Abstract
As companies in the medical industry struggle to develop new ways to gain competitive advantage in the face of increasing generic activity, lower levels of financial investment and demands for higher profitability, maximising patent protection through the use of interlocking additional early stage patents, is one way to help extend patent protection beyond the basic protection of the molecule. This paper outlines some of the areas and methods where additional protection may be available.
Keywords
Get full access to this article
View all access options for this article.